# Question 47

**Type:** Cross-Study Expression Comparison

**Question:** How does ERBB2 mRNA expression vary across different cancer types in TCGA Pan-Cancer Atlas studies?

**Answer:**

# ERBB2 mRNA Expression Across TCGA Pan-Cancer Atlas Cancer Types

Based on the TCGA Pan-Cancer Atlas studies, ERBB2 (HER2) mRNA expression shows significant variation across different cancer types:

## Highest Expression Levels:
1. **Breast Invasive Carcinoma (BRCA)** - Shows the highest and most variable expression, with a subset of tumors showing amplification-driven overexpression (HER2-positive subtype, ~15-20% of cases)
2. **Uterine Corpus Endometrial Carcinoma (UCEC)** - Demonstrates elevated expression in serous subtype
3. **Stomach Adenocarcinoma (STAD)** - Contains a HER2-positive subset (~20% of cases)
4. **Esophageal Carcinoma (ESCA)** - Shows high expression in adenocarcinoma subtype

## Moderate Expression:
- **Bladder Urothelial Carcinoma (BLCA)**
- **Lung Adenocarcinoma (LUAD)**
- **Ovarian Serous Cystadenocarcinoma (OV)**
- **Colorectal Adenocarcinoma (COADREAD)**

## Lower Expression:
- **Glioblastoma (GBM)**
- **Kidney Renal Clear Cell Carcinoma (KIRC)**
- **Acute Myeloid Leukemia (LAML)**

## Key Findings:
- ERBB2 amplification correlates strongly with mRNA overexpression
- Expression levels are clinically relevant for HER2-targeted therapy eligibility
- Pan-cancer analysis reveals therapeutic opportunities beyond breast cancer

Would you like specific expression values or information about ERBB2 alterations in a particular cancer type?

---

## Model Information
- **model**: us.anthropic.claude-sonnet-4-5-20250929-v1:0
- **temperature**: 0.0
- **max_output_tokens**: 1024
- **thinking_enabled**: False
- **thinking_budget_tokens**: 1024
- **response_time_seconds**: 7.11530494003091
- **agent_type**: cbio-qa-null

### Usage
- **input_tokens**: 54
- **output_tokens**: 435
- **total_tokens**: 489
- **cache_creation_input_tokens**: 0
- **cache_read_input_tokens**: 0

---

*Generated on 2026-02-05 01:38:56*